Analyst consensus rating
TScan Therapeutics Analyst Rating: Hold
Direct answer
TScan Therapeutics's consensus rating is Hold.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $1.00.
Forecast evidence checked November 21, 2026.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.15
- Average price target
- $1.00
- High price target
- $1.00
- Low price target
- $1.00
- Low target gap
- +585.4%
- Target upside
- +585.4%
- High target gap
- +585.4%
- Target range width
- 0%
- Consensus rating
- Hold
- Analysts
- 1
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for TScan Therapeutics?
TScan Therapeutics has a verified Hold consensus. The same dataset has an average price target of $1.00.
How far are TScan Therapeutics's low and high targets from the recorded price?
The low target implies +585.4%, while the high target implies +585.4%.
How many analysts are included in TScan Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is TScan Therapeutics's target upside or downside calculated?
The average target of $1.00 is divided by the recorded price of $0.15, then one is subtracted to produce +585.4%. This does not guarantee a future return.
When was TScan Therapeutics's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.